Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Post-Traumatic Stress Disorder

In brief

To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.

Key facts

Study ID

NCT04044664

Run by

Aptinyx

People needed

160

Starts

2019-01-25

Expected to finish

2020-08-05

Last updated by the study team

2022-05-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A primary diagnosis of PTSD [Post Traumatic Stress Disorder, according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders)] with the primary traumatic event occurring ≥12 months prior to screening.
• PCL-5 (PTSD Checklist for DSM-5) ≥38 at screening.
• CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) total score ≥30 at screening.

You may not qualify if…

• Complex PTSD.
• Trauma focused psychotherapies.
• Primary traumatic event occurred prior to 2001.
• Primary traumatic event was followed by further major traumatic life episodes.
• Other psychiatric disorders that is the primary focus of treatment or followed/worsened since exposure to the trauma (except for major depressive disorder or anxiety disorders that followed exposure to the trauma or an anxiety disorder that showed a worsening after trauma)
• Current use of medications with primarily central nervous system activities
• Other clinically significant medical histories that may interfere with completing the study.

Where it is running

• Aptinyx Clinical Site — Tuscaloosa, Alabama, United States
• Aptinyx Clinical Site — Phoenix, Arizona, United States
• Aptinyx Clinical Site — Little Rock, Arkansas, United States
• Aptinyx Clinical Site — Bellflower, California, United States
• Aptinyx Clinical Site — Glendale, California, United States
• Aptinyx Clinical Site — Imperial, California, United States
• Aptinyx Clinical Site — Oakland, California, United States
• Aptinyx Clinical Site — Oceanside, California, United States
• Aptinyx Clinical Site — Orange, California, United States
• Aptinyx Clinical Site — Riverside, California, United States
• Aptinyx Clinical Site — San Diego, California, United States
• Aptinyx Clinical Site — San Marcos, California, United States
• Aptinyx Clinical Site — Santa Ana, California, United States
• Aptinyx Clinical Site — Temecula, California, United States
• Aptinyx Clinical Site — Torrance, California, United States
• Aptinyx Clinical Site — Colorado Springs, Colorado, United States
• Aptinyx Clinical Site — Norwich, Connecticut, United States
• Aptinyx Clinical Site — Jacksonville, Florida, United States
• Aptinyx Clinical Site — Lauderhill, Florida, United States
• Aptinyx Clinical Site — Orlando, Florida, United States
• Aptinyx — Atlanta, Georgia, United States
• Aptinyx Clinical Site — Atlanta, Georgia, United States
• Aptinyx Clinical Site — Hoffman Estates, Illinois, United States
• Aptinyx Clinical Site — Boston, Massachusetts, United States
• Aptinyx Clinical Site — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.